Background: Reactive oxygen species (ROS) production and oxidative stress may be responsible for the onset of several chronic diseases. Usnic acid (UA) is a natural secondary metabolite of lichens with several healthful bioactivities, including antioxidant properties. However, UA is a hydrophobic compound known for its hepatic toxicity. These aspects limit its therapeutic applications. To overcome these drawbacks and improve the pharmacological use of hydrophobic compounds, nanotechnology is widely used. Therefore, the incorporation of UA into appropriate nanocarriers could enhance the bioactivity of UA by increasing its solubility.
Objective: The aim of this work was to improve the solubility of UA and its bioactivity in the absence of cytotoxicity.
Methods: In this study, UA loaded liposomes (UA-LP) were developed. The formulations were chemically and physically characterized, and an in vitro release study was performed. Free UA and UA-LP were tested on RAW 264.7 murine macrophages in terms of cytotoxicity, intracellular ROS production, and NO release in the absence or presence of pro-oxidant LPS stimulus.
Results: UA-LP showed excellent physical and chemical stability during storage and improved solubility of UA. UA-LP showed an antioxidant effect in the absence of cytotoxicity compared with free UA on LPS-exposed macrophages.
Conclusion: For the first time, liposomal formulation improved the beneficial action of UA in terms of solubility and antioxidant activity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1567201820666230111112415 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Layer-by-Layer Biopolymer-Coated Deformable Liposomes-In Situ Gel: A Hybrid Strategy for Enhanced Ocular Delivery of Itraconazole: In Vitro and In Vivo Appraisal.
Gels
December 2024
Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11495, Saudi Arabia.
Itraconazole (ITZ) is a potent antifungal agent. Its oral administration is associated with systemic toxicity, and its efficacy in ocular formulations is limited. This study aims to enhance ITZ's ocular permeation and antifungal efficacy by loading it into deformable liposomes (DLs) based on Tween 80 (T) or Poloxamer 188 (P).
View Article and Find Full Text PDFA complete sojourn on nanotechnological advancements and nanocarrier applications in psoriasis management.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Department of Pharmaceutics, ISF College of Pharmacy, GT Road, Moga, 142001, Punjab, India.
Psoriasis, a chronic autoimmune and non-communicable skin disease, affects 2-3% of the global population, creating a significant financial burden on healthcare systems worldwide. Treatment approaches are categorized based on disease severity, with first-line therapy focusing on topical treatments and second-line therapy encompassing phototherapy, systemic therapy, and biological therapy. Transdermal drug delivery methods present a promising alternative by enhancing drug absorption through the skin, potentially improving therapeutic outcomes while minimizing systemic adverse effects.
View Article and Find Full Text PDFNanocurcumin in myocardial infarction therapy: emerging trends and future directions.
Front Bioeng Biotechnol
January 2025
Department of Cardiology, Yantaishan Hospital, Yantai, Shandong, China.
Myocardial infarction (MI) is the leading cause of morbidity and mortality worldwide. Curcumin has been observed to significantly reduce pathological processes associated with MI. Its clinical application is limited due to its low bioavailability, rapid degradation, and poor solubility.
View Article and Find Full Text PDFOptimized Rutin-incorporating PEGylated Nanoliposomes as a Model wit Remarkable Selectivity Against PANK1 and MCF7 Cell Lines.
Anticancer Agents Med Chem
January 2025
Cell Therapy Center, The University of Jordan, Amman, 11942, Jordan.
Background: This study aims to enhance the delivery of polyphenols using nanotechnology.
Objective: To develop and evaluate liposomal formulations for improved delivery and stability of polyphenols, specifically focusing on Rutin.
Methods: Liposomal formulations were meticulously prepared via the Thin-Film Hydration method.
Tofacitinib in focus: Fascinating voyage from conventional formulations to novel delivery systems.
Int J Pharm
January 2025
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKMs NMIMS, V.L. Mehta Road, Vile Parle (W), Mumbai, Maharashtra 400056, India. Electronic address:
Tofacitinib, a Janus kinase (JAK) inhibitor, has emerged as a primary therapeutic agent for managing autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, dermatitis and ulcerative colitis. By inhibiting the phosphorylation of JAK enzymes, tofacitinib prevents their activation within the JAK-STAT signaling pathway, which is vital for inflammatory responses. However, the tofacitinib delivery presents significant challenges, including pH-dependent solubility, poor permeability and susceptibility to oral degradation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!